Fidelity Investments
EVOK

Fidelity Investments’s Evoke Pharma EVOK Stock Holding History

Fidelity Investments’s Portfolio EVOK Stock Details EVOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-301
Closed -$792 – 5441
2025
Q2 		$792 Buy
+301
New +$866 ﹤0.01% 4990
2024
Q3 		– Sell
-6
Closed -$38 – 5558
2024
Q2 		$38 Buy
+6
New +$36 ﹤0.01% 5096
2022
Q2 		– Hold
0
– – – 5071
2022
Q1 		– Sell
-1
Closed -$80 – 5115
2021
Q4 		$0 Buy
+1
New +$140 ﹤0.01% 4518
2021
Q3 		– Hold
0
– – – 4541
2021
Q2 		– Hold
0
– – – 4426

Other funds holding EVOK

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
NWMG
National Wealth Management Group Cincinnati, Ohio $323M AUM 39.23% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management Milwaukee, Wisconsin $187B AUM 21.7% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fidelity Investments's EVOK Position: Q3 2025 in Review

Fidelity Investments sold out of Evoke Pharma (EVOK) in Q3 2025, closing a stake of 301 shares — an estimated $792 sold.

Fidelity Investments first reported a position in EVOK in Q4 2021 and held it in 3 quarters. The position peaked at $792 in Q2 2025. 15 funds tracked by Wall St. Rank hold EVOK as of Q3 2025.

  • Fidelity Investments reported no remaining Evoke Pharma position as of Q3 2025 after selling out during the quarter.
  • Fidelity Investments sold 301 Evoke Pharma shares in Q3 2025, an estimated $792.
  • Fidelity Investments first reported a position in Evoke Pharma in Q4 2021 and held it in 3 quarters.
  • Fidelity Investments's Evoke Pharma position peaked at $792 in Q2 2025.
  • 15 funds tracked by Wall St. Rank held Evoke Pharma as of Q3 2025.

Based on Fidelity Investments's 13F filing for Q3 2025, filed 13 Nov 2025.